OCULAR THERAPEUTIX, INC
OCUL evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for OCUL—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · OCUL
Ocular Therapeutix is a biopharmaceutical company focused on developing and commercializing therapies for retinal diseases, with a lead product candidate AXPAXLI in Phase 3 trials for wet age-related macular degeneration and diabetic retinal disease, and a marketed product DEXTENZA.
Key risk: Clinical trial delays
BioSniper Score
Based on 6 of 6 signals
Market Cap
$2.28B
Cash Runway
27.4 moLead Asset
AXPAXLI (Phase 3)
Next Catalyst
Phase3_Topline · Jan 8, 2027Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 5 clinical trials · 5 catalysts · 1 FDA decision for OCULAR THERAPEUTIX, INC.
Ocular Therapeutix is a biopharmaceutical company focused on developing and commercializing therapies for retinal diseases, with a lead product candidate AXPAXLI in Phase 3 trials for wet age-related macular degeneration and diabetic retinal disease, and a marketed product DEXTENZA.
- Lead product candidate AXPAXLI (OTX-TKI) is in Phase 3 clinical trials (SOL-1, SOL-R, SOL-X) for wet age-related macular degeneration and a Phase 3 trial (HELIOS-3) for diabetic retinal disease [sec_mda · as of 2026-08-03].
- DEXTENZA is a marketed product generating revenue; the company reported total revenue of $13.5M for the six months ended June 30, 2026 [sec].
- Cash and equivalents were $600.3M as of June 30, 2026, with an accumulated deficit of $1,324.4M as of the same date [sec_mda · as of 2026-08-03].
- Net loss for the six months ended June 30, 2026 was $78.8M, reflecting ongoing investment in clinical programs [sec].
- The company has a credit agreement with a minimum liquidity covenant of $20.0M and total debt of $72.8M as of June 30, 2026 [sec_mda · as of 2026-08-03].
What works
- AXPAXLI is in multiple Phase 3 registrational programs (SOL-1, SOL-R, SOL-X for wet AMD; HELIOS-3 for diabetic retinal disease), indicating a broad development pipeline [sec_mda · as of 2026-08-03].
- DEXTENZA provides a commercial revenue stream, with the company reporting $13.5M in total revenue for the six months ended June 30, 2026 [sec].
- Cash position of $600.3M as of June 30, 2026 provides a substantial runway to fund planned operations and clinical trials [sec_mda · as of 2026-08-03].
What to weigh
- The company has an accumulated deficit of $1,324.4M as of June 30, 2026 and expects to continue incurring losses as it advances clinical trials [sec_mda · as of 2026-08-03].
- Research and development expenses increased to $120.4M for the six months ended June 30, 2026, up from $93.9M in the prior year period, reflecting high cash burn [sec_mda · as of 2026-08-03].
- The company faces risks related to clinical trial timing, regulatory approvals, and reliance on third parties, as detailed in its risk factors [sec · filed 2025-12-18].
From the filings
Quoted directly from source documents.
Catalyst timeline
- 2027-01-08 · Phase3_Topline — Phase 3 Topline: A Phase 3, Multicenter, Double-Masked, Randomized, Parallel Group Study to Evaluate the Efficacy and — Topline data from a Phase 3 trial of AXPAXLI for wet AMD; results will inform regulatory path.
- 2027-03-01 · Phase3_Topline · non-proliferative — Phase 3 Topline: A Phase 3, Multicenter, Double-Masked, Randomized, 3-Arm Parallel Group Study to Evaluate the Effica — Topline data from a Phase 3 trial of AXPAXLI for non-proliferative diabetic retinal disease.
- 2027-09-27 · Phase3_Topline — Phase 3 Topline: A Phase 3, Multicenter, Double-Masked, Randomized, Parallel-Group Study to Evaluate the Efficacy and — Topline data from another Phase 3 trial of AXPAXLI; further data on efficacy and safety.
- 2030-08-01 · Phase3_Topline — Phase 3 Topline: A Phase 3b, Multicenter, Open-Label, Extension Study to Evaluate Long-Term Safety of Intravitreal OT — Long-term safety extension study for AXPAXLI; results will support chronic use profile.
- 2041-04-26 · Patent_Expiry · DEXTENZA — Patent/Exclusivity Expiry: DEXTENZA — Patent expiry for DEXTENZA could open market to generic competition.
Risks & what to watch (4)›
Key risks
- Clinical trial delays — Uncertainties regarding timing, conduct, and data availability from ongoing trials, including SOL-1 [sec · filed 2025-12-18].
- Regulatory approval risk — Dependence on FDA approval for AXPAXLI and other candidates; failure could halt development [sec · filed 2025-09-30].
- Cash burn and debt — High R&D expenses and accumulated deficit of $1,324.4M; debt of $72.8M with liquidity covenant [sec_mda · as of 2026-08-03].
- Commercialization dependence — Reliance on DEXTENZA revenue and reimbursement codes; limited product diversification [sec · filed 2025-09-30].
What to watch
- Topline data from Phase 3 SOL-1 trial for AXPAXLI in wet AMD expected January 8, 2027 [catalyst].
- Topline data from Phase 3 trial for AXPAXLI in non-proliferative diabetic retinal disease expected March 1, 2027 [catalyst].
- Topline data from another Phase 3 trial for AXPAXLI expected September 27, 2027 [catalyst].
- Patent expiry for DEXTENZA on April 26, 2041, which could affect long-term revenue [catalyst].
Sources: SEC filings · SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run OCULAR THERAPEUTIX, INC through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available OCULAR THERAPEUTIX, INC facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
27.4 months
D/E 0.29 · 0% dilution
Lead: Approved
2 candidates
5 upcoming, next in ~131d
0 buys · 5 sells (180d)
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
267
Total value held
$1.50B
| Holder | Shares | Value |
|---|---|---|
| fmr llc | 32,653,764 | $276.6M |
| deep track capital, lp | 19,686,282 | $166.7M |
| vanguard capital management llc | 17,438,078 | $147.7M |
| blackrock, inc. | 16,132,931 | $136.6M |
| alliancebernstein l.p. | 4,129,687 | $50.1M |
| state street corp | 4,708,419 | $39.9M |
| geode capital management, llc | 4,529,185 | $38.4M |
| logos global management lp | 3,850,000 | $32.6M |
| woodline partners lp | 3,335,218 | $28.2M |
| octagon capital advisors lp | 3,166,600 | $26.8M |
Showing top 10 of 267 institutional holders of OCULAR THERAPEUTIX, INC. Open the full 13F history after sign-in.
Short Interest
as of May 19, 2026- % of float
- 13.4%
- Days to cover
- 7.5
- Shares short
- 24,793,045
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
OCUL short interestGovernance
Frequently asked questions
What is the AI investment thesis for OCULAR THERAPEUTIX, INC?
Ocular Therapeutix is a biopharmaceutical company focused on developing and commercializing therapies for retinal diseases, with a lead product candidate AXPAXLI in Phase 3 trials for wet age-related macular degeneration and diabetic retinal disease, and a marketed product DEXTENZA.
What is OCULAR THERAPEUTIX, INC's lead drug candidate?
OCULAR THERAPEUTIX, INC's most advanced tracked candidate is AXPAXLI (Phase 3) for Wet age-related macular degeneration (wet AMD) and non-proliferative diabetic retinopathy (NPDR).
What is OCULAR THERAPEUTIX, INC's next catalyst?
OCULAR THERAPEUTIX, INC's next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 3, Multicenter, Double-Masked, Randomized, Parallel Group Study to Evaluate the Efficacy and" — expected January 8, 2027.
Who is the CEO of OCULAR THERAPEUTIX, INC?
Dr. Pravin U. Dugel M.D. is the chief executive officer of OCULAR THERAPEUTIX, INC (OCUL).
Where is OCULAR THERAPEUTIX, INC headquartered?
OCULAR THERAPEUTIX, INC (OCUL) is headquartered in Bedford, MA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.